News & Blog

Hereditary Ataxias Added as Eligible Condition for CDMRP Funding!

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Strong Partnership Funds the 2022 Ataxian Athlete Initiative (AAI) for People with Ataxia

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Lexeo Announces FDA Clearance of IND Application for LX2006 for Friedreich’s Ataxia Cardiomyopathy

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006

LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)